Skip to main content
OpenTrials
Completed

NCT Number: NCT06276361

Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia

This is a single ascending dose phase 1 study to evaluate the pharmacokinetics (PK), safety, and tolerability of a single intramuscular (IM) injection of quarterly Risperidone (QUAR) for different formulations and dose strengths in participants with schizophrenia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Investigational Site

Amman, Jordan

About this study

The study will assess the PK, safety and tolerability of QUAR when administered as a single IM injection, in patients with schizophrenia. The study will be conducted with 3 different dose strengths and up to two formulations.

After eligibility confirmation, an oral treatment period follow by a washout period will be performed before QUAR IM administration.

The different cohorts will be administered with one of the following dosages of Risperidone QUAR:

Cohort 1/2: Formulation 1 or 2. Dose level 1 (Gluteal); Cohort 1a/2a: Formulation 1 or 2. Dose level 2 (Gluteal); Cohort 1b/2b: Formulation 1 or 2. Dose level 3 (Gluteal); Cohort 1c/2c: Formulation 1 or 2. Dose level 3 (Deltoid);

The progression to the next cohorts will take place after a clinical safety assessment. Several blood samples for plasma pharmacokinetic (PK) assessments will be obtained pre-dose and post-dose. Safety assessments will be conducted at each pre-specified time points.

After assessment of Cohort 1 (formulation 1, Dose Level 1, -gluteus-) progression to the next cohort with same formulation and escalating dose will take place (Cohort 1a -gluteus-). After assessment of Cohort 1a, progression and randomization (gluteus/deltoid) to the next cohorts with same formulation and escalating dose will take place (Cohort 1b -gluteus- and Cohort 1c -deltoid-). In this scenario, none of the Cohorts 2 will be conducted.

If the assessment for Cohort 1 is not adequate, none of the subsequent Cohorts 1 (a/b/c) will be conducted and progression to the next cohort (Cohort 2) with different formulation and same level of dose as Cohort 1 will take place (Cohort 2: Formulation 2, Dose Level 1 -gluteus-). After assessment of Cohort 2, progression to the next cohort with same formulation and escalating dose will take place (Cohort 2a -gluteus-). After assessment of Cohort 2a, progression and randomization (gluteus/deltoid) to the next cohorts with same formulation and escalating dose will take place (Cohort 2b -gluteus- and Cohort 2c -deltoid-).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Capable of providing informed consent.
  • Male or female aged ≥ 18 years to < 65 years with BMI ≥17.0 to ≤35.0 kg/m2
  • Current diagnosis of schizophrenia, according to the Diagnostic and DSM-5 criteria.
  • Medically stable over the last month, and psychiatrically stable without significant symptom exacerbation over the last three months based on the investigator's judgment
  • currently taking oral risperidone as maintenance therapy
  • Score of ≤ 4 (moderately ill at most) on the Clinical Global Impression - Severity of Illness (CGI-S)
  • If a sexually active female of childbearing potential, using a medically accepted method of birth control.

Exclusion criteria

  • Presence of an uncontrolled, unstable, clinically significant medical condition that in the opinion of the investigator could interfere with the interpretation of safety and PK evaluations
  • If female, a positive serum pregnancy test, or planning to become pregnant between signing informed consent and 1 month after the last dose of study drug or is breastfeeding a child.
  • History of neuroleptic malignant syndrome and current or past history of clinically significant tardive dyskinesia.
  • The participant has a primary diagnosis other than schizophrenia diagnosis that is primarily responsible for current symptoms and functional impairment
  • Positive test result for drugs of abuse or alcohol unless the positive finding can be accounted for by documented prescription use.
  • In the investigator's opinion, at imminent risk of committing self-harm or harm to others.
  • Unwilling to discontinue any of the prohibited medications prior to the baseline visit or unable to safely washout such medication without significant destabilization or increased risk of self-harm (suicide).
  • Receipt study drug in another investigational study in the last 90 days.
  • Current participation in any other clinical trial.

Treatment and study plan

Oral risperidone; QUAR F1/2, Dose 1 - Gluteal

Drug

Dose level 1

Oral risperidone; QUAR F1/2, Dose 2 - Gluteal

Drug

Dose level 2

Oral risperidone; QUAR F1/2, Dose 3 - Gluteal

Drug

Dose level 3

Oral risperidone; QUAR F1/2, Dose 3 - Deltoids

Drug

Dose level 3

Primary outcomes

  1. λz

    Time frame: Following Oral and QUAR administration until day 17 or 196 respectively

    Terminal elimination rate constant

  2. t1/2

    Time frame: Following Oral and QUAR administration until day 17 or 196 respectively

    Terminal elimination half-life

  3. Tmax

    Time frame: Following Oral and QUAR administration until day 17 or 196 respectively

    Time to peak concentration

  4. Cmax

    Time frame: Following Oral and QUAR administration until day 17 or 196 respectively

    Peak plasma concentration

  5. Cmin

    Time frame: Following Oral and QUAR administration until day 17 or 196 respectively

    Minimum plasma concentration

  6. Clast

    Time frame: Following Oral and QUAR administration until day 17 or 196 respectively

    Last observed plasma concentration

  7. AUC0-t

    Time frame: Following Oral and QUAR administration until day 17 or 196 respectively

    Area under the curve

  8. AUCinf

    Time frame: Following QUAR administration until day 196

    Area under the curve

  9. AUCextrap

    Time frame: Following QUAR administration until day 196

    Area under the curve

  10. Vd/F

    Time frame: Following Oral and QUAR administration until day 17 or 196 respectively

    Apparent volume of distribution

  11. Cl/F

    Time frame: Following Oral and QUAR administration until day 17 or 196 respectively

    Apparent total body clearance

Sponsors and collaborators

Lead sponsor

Rovi Pharmaceuticals Laboratories

Industry

Registry information

Official study title

A Single Ascending Dose Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Single Intramuscular Injection of Quarterly Risperidone (QUAR) for Different Formulations and Dose Strengths in Participants With Schizophrenia (QUARTZ Study)

Acronym: QUARTZ

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Feb 26, 2024
Registry last updated
Sep 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.